Stay updated with breaking news from Aflibercept Eylea. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The "Global Diabetic Retinopathy Market: Size, Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive...
Dublin, Oct. 27, 2022 (GLOBE NEWSWIRE) -- The "Global Diabetic Retinopathy Market: Size, Share, Application Analysis, Regional Outlook, Growth Trends,...
Anti-VEGF will Remain Preferred Product in the Global Diabetic Macular Edema Market
A robust pipeline of potential new treatments currently in Phases II and III is expected to drive the Diabetic Retinopathy Market ahead. LAS VEGAS, May 12, 2021 /PRNewswire/ -- DelveInsight's
Cipla announced that its subsidiary, Cipla Gulf FZ LCC (Cipla Gulf) is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia and New Zealand. As part of this strategic alliance, Cipla Gulf will be responsible for commercialization of patented biosimilars of the biologic medicine brands, Aflibercept (Eylea), Ustekimumab (Stelara), Denosumab (Prolia, Xgeva) and Golimumab (Simponi). These are leading products covering therapeutic categories across immunology, osteoporosis, oncology as well as ophthalmology (eg. Aflibercept is indic...